European Commission approves Merck Serono’s Kuvan
Merck KGaA says that regulators in Europe have given the go-ahead for the firm to start selling Kuvan which treats a rare brain disorder.
Read MoreAuthor: Kevin Grogan
Excitement grows over GSK’s malaria jab
GlaxoSmithKline has been boosted by the publication of two studies which reveal that “the world’s most clinically advanced malaria vaccine candidate” provides both infants and young children with significant protection against the disease.
Read MoreAstraZeneca and Targacept drug fails in CDS trial
AstraZeneca and partner Targacept have suffered a clinical setback with the news that a mid-stage trial of their experimental compound AZD3480 failed to demonstrate effectiveness in schizophrenia patients.
Read MorePooled Xarelto data underlines superiority over Lovenox
Bayer has presented more positive data on Xarelto which the firm says underlines the superior efficacy of the anticoagulant compared with the current gold standard treatment, Sanofi-Aventis’ Lovenox.
Read MoreForest/Cypress present more strong Phase III milnacipran data
Forest Laboratories and Cypress Bioscience have posted more positive late-stage data on milnacipran for the treatment of fibromyalgia.
Read More- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
